## NDAQ: Nasdaq, Inc. - XLF: Financial Services

### Executive Summary

No thesis match: MRS_10 0.4% below STRENGTH zone (3.0-6.0%); PEG 1.40 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($87.68)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Form 424B2 GOLDMAN SACHS GROUP INC**
- Source: StreetInsider | 20251208T190913 | Neutral | Relevance: 74%
-  Goldman Sachs Group Inc. has filed Form 424B2 for Autocallable Contingent Coupon Underlier-Linked Notes. These notes are linked to the Russell 2000 Index, Nasdaq-100 Technology Sector Index, and VanEck Semiconductor ETF, offering potential monthly coupons if underlier levels meet specific thresholds. The notes are subject to automatic redemption and significant risks, including the creditworthiness of GS Finance Corp. and The Goldman Sachs Group, Inc., and potential loss of the entire investment.

**2. Lucid Interim CEO to Speak at the 53rd Annual NASDAQ Investor Conference held in Association with Morgan Stanley**
- Source: KXAN Austin | 20251208T090000 | Neutral | Relevance: 73%
-  Lucid Group, Inc. announced that Interim CEO Marc Winterhoff will participate in a fireside chat at the 53rd Annual NASDAQ Investor Conference held in Association with Morgan Stanley on December 10 at 11:30 am GMT (6:30 am EST). The session will be webcast live on Lucid's investor relations website, with a replay available for 90 days. Lucid is a Silicon Valley-based technology company known for its advanced EVs, the Lucid Air and Lucid Gravity SUV.

**3. Ascent Solar Technologies Closes Up To $5.5M Private Placement Priced At-The-Market Under Nasdaq Rules**
- Source: SolarQuarter | 20251209T090916 | Somewhat-Bullish | Relevance: 64%
-  Ascent Solar Technologies announced the completion of a private placement, selling over one million shares of common stock and accompanying warrants at $1.95 per share. The offering, priced at-the-market under Nasdaq rules, generated approximately $2 million in gross proceeds, with the potential for an additional $3.5 million if all warrants are exercised. The company plans to use the net proceeds for general working capital needs.

**4. Guarantor: JPMorgan Chase & Co.**
- Source: StreetInsider | 20251209T164617 | Neutral | Relevance: 63%
-  JPMorgan Chase Financial Company LLC has filed a preliminary pricing supplement for Uncapped Accelerated Barrier Notes linked to the least performing of the Dow Jones Industrial Average, Nasdaq-100 Index, and S&P 500 Index. These notes, fully guaranteed by JPMorgan Chase & Co., are designed for investors seeking an uncapped return of at least 1.30 times the appreciation of the least performing index, but investors risk losing some or all of their principal. The notes are expected to price on or about December 30, 2025, and mature on January 5, 2029.

**5. Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV**
- Source: Oak Ridger | 20251207T035342 | Neutral | Relevance: 63%
-  RedChip Companies will feature interviews with Calidi Biotherapeutics (NYSE American:CLDI) and Nova Minerals Limited (Nasdaq:NVA) on its "RedChip Small Stocks, Big Money™" show, airing on Bloomberg TV this Saturday, December 6, at 7 p.m. ET. Calidi's CEO, Eric Poma, Ph.D., will discuss their RedTail platform for targeted genetic medicine, while Nova Minerals' CEO, Christopher Gerteisen, will detail the strategy for their Estelle Project, a significant gold and critical minerals asset in Alaska. The interviews will highlight each company's potential for growth and value creation for shareholders.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Morgan Stanley | $110 | $97 | +13% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Morgan Stanley | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 4 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.0% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.4% (+6.9%)
- Investor AB: 10.2% (0.0%)
- Blackrock Inc.: 7.0% (+8.3%)
- Wellington Managemen: 7.0% (-3.5%)
- Massachusetts Financ: 4.6% (-3.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.0% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.40 suggests fair value with growth premium. Forward P/E 23.8x stretched relative to 11% growth. Quality metrics strong (margin 20%). Analyst sentiment positive (1 raises, avg +13%). Institutional flow bearish (5 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $52.1B |
| Beta | 1.02 |
| 52W Range | $64.84 - $97.63 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.40 |
| Forward P/E | 23.8 |
| Current P/E | 26.5 |
| YoY Growth | 11.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.6% to 0.4% (+3.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.6pp (needs >3.0% for momentum thesis). MRS_5 at 0.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 60.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.42% (CS: 63) | Neutral |
| RSI_14 | 59.8 | Neutral |
| MACD Histogram | 0.29 | Bullish |
| vs SMA20 | 1.026x | Above |
| vs SMA50 | 1.029x | Above |
| vs SMA200 | 1.060x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $90.72
- **Stop Loss:** $87.68 (3.4% risk)
- **Target:** $93.76 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 164
- **Position Value:** $14,878.08
- **Portfolio %:** 14.88%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-01-28 (Est: $0.91)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.85 | $0.88 | +3.7% |
| 2025Q2 | $0.81 | $0.85 | +4.6% |
| 2025Q1 | $0.77 | $0.79 | +2.5% |
| 2024Q4 | $0.75 | $0.76 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*